News & Events
-
May 2, 2023
C-Path’s CDRC Meeting Highlights the Importance of Drug Repurposing
The Critical Path Institute’s CURE Drug Repurposing Collaboratory and FDA hosted their annual meeting April 18-20 to bring together stakeholders in drug repurposing. TUCSON, Ariz., May 4, 2023 — The CURE Drug Repurposing Collaboratory (CDRC) held a three-day annual meeting, April 18- 20, in Crystal City, VA. The event, hosted for both live and virtual...... -
April 7, 2022
Doctor With Rare Disease And No Answers Decides To Find His Own Cure
David Fajgenbaum was diagnosed with Castleman disease as a medical student. In Chasing My Cure, he recounts crowd-sourcing his own treatment with a global network of doctors, scientists and patients.
-
April 7, 2022
Castleman’s Disease: Behind the Mystery of Rare Disease
We’re going Behind the Mystery of two rare diseases: Castleman disease and chondrosarcoma.
There are no effective treatment options for people with unresectable or metastatic chondrosarcoma despite many attempts by multiple pharmaceutical companies over the past few decades. Inhibrx, a clinical-stage biotechnology company, is dedicated to helping people with life-threatening conditions. They are developing a therapeutic option for chondrosarcoma called INBRX-109, which is currently in clinical trials.
-
March 31, 2021
Cures Within Reach Names CURE ID as 2021 Patient Impact Awardee
Cures Within Reach, a global nonprofit leading the use of repurposing research to help improve patients’ lives, has awarded CURE ID at the FDA and NCATS/NIH as the recipient of the 2021 Golan Christie Taglia Patient Impact Philanthropy Award part of its 2021 Patient Impact Award recipients of the Global Health Repurposing Awards. C-Path’s Cure Drug Repurposing Collaboratory (CDRC),...... -
June 11, 2020
From the Regulatory Affairs Professional Society (RAPS): FDA’s CURE ID app gets a COVID-19 refresh
An online case reporting platform has been optimized for COVID-19 and will be the springboard for a new public-private drug repurposing collaboration.
The CURE ID online platform was developed to allow clinicians to report off-label uses of drugs to treat infectious diseases, with the goal of generating hypotheses for further study of difficult-to-treat infectious diseases. The internet repository of these cases can also be accessed by clinicians and other users, with the option to view aggregated datasets as well as the individual case reports. The platform can be used via a computer browser or Apple and Android-based smartphone apps. Full article here.